Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Candida parapsilosis in the blood smear of an injection drug user.

ABSTRACT:

SUBMITTER: Liapis K

PROVIDER: S-EPMC3176845 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Candida parapsilosis in the blood smear of an injection drug user.

Liapis Konstantinos K

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110606 13

PMID: 21646463

Similar Datasets

Homo sapiens whole blood infected with Candida spp. (here: Candida parapsilosis)

Project description:Homo sapiens fresh whole blood was infected with Candida parapsilosis. RNA-pool of both species extracted at 0min (control), 15, 30, 60, 120, 240 min. Samples are rRNA depleted. Measurement of Homo sapiens gene expression.

2018-12-26 | GSE114177 | GEO

Characterisation of Candida parapsilosis CYP51 as a Drug Target Using Saccharomyces cerevisiae as Host.

Project description:The fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) is required for the biosynthesis of fungal-specific ergosterol and is the target of azole antifungal drugs. Despite proven success as a clinical target for azole antifungals, there is an urgent need to develop next-generation antifungals that target CYP51 to overcome the resistance of pathogenic fungi to existing azole drugs, toxic adverse reactions and drug interactions due to human drug-metabolizing CYPs. Candida parapsilosis is a readily transmitted opportunistic fungal pathogen that causes candidiasis in health care environments. In this study, we have characterised wild type C. parapsilosis CYP51 and its clinically significant, resistance-causing point mutation Y132F by expressing these enzymes in a Saccharomyces cerevisiae host system. In some cases, the enzymes were co-expressed with their cognate NADPH-cytochrome P450 reductase (CPR). Constitutive expression of CpCYP51 Y132F conferred a 10- to 12-fold resistance to fluconazole and voriconazole, reduced to ~6-fold resistance for the tetrazoles VT-1161 and VT-1129, but did not confer resistance to the long-tailed triazoles. Susceptibilities were unchanged in the case of CpCPR co-expression. Type II binding spectra showed tight triazole and tetrazole binding by affinity-purified recombinant CpCYP51. We report the X-ray crystal structure of ScCYP51 in complex with VT-1129 obtained at a resolution of 2.1 Å. Structural analysis of azole-enzyme interactions and functional studies of recombinant CYP51 from C. parapsilosis have improved understanding of their susceptibility to azole drugs and will help advance structure-directed antifungal discovery.

| S-EPMC8781857 | biostudies-literature

Candida parapsilosis

Project description:Loss of sterol demethylase activity reduces both azole and echinocandin antifungal susceptibility in a clinical isolate of C. parapsilosis

| PRJNA386918 | ENA

Candida parapsilosis

Project description:Candida parapsilosis WGS

| PRJNA1068185 | ENA

Candida parapsilosis

Project description:Candida parapsilosis Genome sequencing and assembly

| PRJNA1173375 | ENA

Candida parapsilosis

Project description:Transcriptional profile of Candida parapsilosis CLIB214 versus UPC2 delete, both at 1% oxygen (hypoxia)

| PRJNA154481 | ENA

Candida parapsilosis

Project description:The APSES Transcription factor Efg1 regulates a novel phenotype switch in Candida parapsilosis [ChIP-seq].